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Objective: To examine the effect of donepezil for the treatment of cognitive and behav-
ioral disorders associated with thalamic lesions in a 45-year-old male who suffered an
infarct in the left thalamus. Background: Recent studies suggest that donepezil may
improve executive functions impairments due to subcortical ischemic lesions. Method:
The effects of donepezil were analyzed in a single-case of thalamic infarction with cognitive
and behavioral alterations in an open label study. Results: Signiﬁcant behavioral modiﬁca-
tions related to improved performances in executive functions were observed with the
treatment. Conclusion:The results suggest that donepezil may have signiﬁcant effect on
executive functions that can alter behavioral outcomes after thalamic infarctions.
Keywords: donepezil, vascular dementia, vascular subcortical cognitive impairment, thalamus, dysexecutive
syndrome, stroke
INTRODUCTION
Thalamic infarcts can be responsible for cognitive, emotional
and/or behavioral alterations with signiﬁcant impact on activities
of daily life (Roman et al., 2005). Donepezil is a cholinesterase
inhibitor currently approved for the treatment of Alzheimer’s
Disease that may also provide some beneﬁts in vascular demen-
tia and vascular cognitive impairment (Erkinjuntti et al., 2004).
Despite the absence of appropriate evaluation of executive func-
tions in previous vascular dementia trials, the results of a recent
placebo-controlled studyperformed indemented aswell as innon-
demented CADASIL patients strongly support that donepezil may
mainly improve executive functions in the presence of subcortical
ischemic lesions (Dichgans et al., 2008). Beneﬁts of cholinesterase
inhibitors on behavior and cognition have been also reported on
other conditions that can affect cholinergic pathways connect-
ing cortical and subcortical structures, such as traumatic brain
injury (Tenovuo, 2005). Moreover, donepezil has also been sug-
gested for the treatment of depression and apathy, both symptoms
being, at least, partially modulated by cholinergic innervations
(Whyte et al., 2008). All these conditions affect cholinergic nuclei
like the basal forebrain, thalamus, and their innervations to the
cerebral cortex (Tenovuo, 2005). These ﬁndings are consistent
with neuro-anatomical evidence and clinical trials suggesting that
cholinergic pathways are involved in cognition and neuropsychi-
atric symptoms, especially apathy (Selden et al., 1998; Reynolds
et al., 2011).
Damage to the frontal cortex and to the subcortical related
structures are presumably responsible for the cognitive and
behavioral symptoms gathered into the so-called “dysexecutive
syndrome” (DS; Chaytor and Schmitter-Edgecombe, 2007). The
DS can be analyzed according to its cognitive and behavioral com-
ponents usingdedicated tests (Chaytor andSchmitter-Edgecombe,
2007). Structured and reliable questionnaires have also been
recently developed to assess the manifestations of DS in daily
life since there is only a weak relationship between the results of
neuropsychological testing and the daily life consequences of this
syndrome. This discrepancy is presumably related to the lack of
behavioral evaluation in the neuropsychological testing (Chay-
tor and Schmitter-Edgecombe, 2007). The Dysexecutive Ques-
tionnaire (DEX) is a 20-item questionnaire that uses a 5-point
Likert scale to assess the dysexecutive symptoms. The DEX scores
range from 0 to 80 points, with higher scores reﬂecting higher
difﬁculties in daily life. The DEX questionnaire belongs to the
“BehavioralAssessment of DS,”battery anddescribeswith fair con-
ﬁdence the non-routine everyday problems arising from executive
dysfunction (Wilson et al., 1998).
We report a single-case with a left thalamic infarction and
behavioral disturbances that was treated with donepezil for
6months using a open label study with an off-on-off design. As
an effect of the treatment, we hypothesized an improvement of
dysexecutive symptoms and apathy.
CASE REPORT
L.G. was a 45-year-old male, right-handed, with no history of
neurological or psychiatric disease. He worked as a supermarket
store manager. He presented an amnesic syndrome and behav-
ioral disturbances of sudden onset in the absence of focal signs at
neurological examination.
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These clinical manifestations occurred with an isolated infarc-
tion located on magnetic resonance imaging (MRI) in the ventro-
lateral and ventroanterior nucleus of the left thalamus (Figure 1).
He received a full etiology study that did not reveal any etiology.
Since this event, the patient was unable to resume his previous
work and only sustained temporary jobs. The patient and his wife
FIGURE 1 | Brain Nuclear Magnetic Resonance.T2 DWI axial (left) and
coronal (right) views of the patient showing left thalamic infarction in the
anterior nuclei, ventral lateral nuclei and anterior part of the median dorsal
nuclei. The mamillo-thalamic tract and internal medullary lamina are also
compromised. No other ischemic lesions were found.
complained about memory disturbances and inability to carry on
his job.Hiswife also referredbehavior disturbances,mainly apathy,
and difﬁculty to plan. He did refer neither depressive symptoms,
nor anxiety.
Two years later, he was ﬁrst evaluated by neuropsychological
testing. Both the patient and his wife conﬁrmed that there was
no signiﬁcant change in his cognitive functioning over the two
previous years. The global cognitive performances were assessed
using the mini-mental state examination (MMSE; Folstein et al.,
1975), the working memory using the Digit Span and the verbal
learning capabilities using the free and cued selective reminding
test (FCSRT; Grober et al., 2008). The examination of executive
functions was carried out using the Frontal Assessment at Bedside
(Dubois et al., 2000), the category and literal verbal ﬂuency tests
and the modiﬁed version of Wisconsin card sorting test (MWCST;
Van den Broek et al., 1993). The everyday memory difﬁculties
were evaluated using the Mac Nair’s Cognitive Difﬁculties Scale,
which was applied to both the patient and his wife (Derouesne
et al., 1993). The latter was also questioned using the neuropsychi-
atric inventory (NPI) and the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Inventory (ADCS-ADL; Cum-
mings et al., 1994; Galasko et al., 1997). Finally, the dysexecutive
behavior in everyday life was assessed using theDEXquestionnaire
applied to the patient’s wife (Wilson et al., 1998).
Table 1 | Patient scores in cognitive battery and behavioral questionnaires for baseline, 3 and 6months of treatment and 3months after
treatment discontinuation.
Test (max. test score) Baseline 3Months 6Months 3Months
after discontinuation
Global cognitive efﬁciency
MMSE (/30) 26 27 27 28
Attention and working memory
Direct digit span (/7) 5 5 4 5
Reverse digit span (/7) 4 4 5 4
Episodic memory
Verbal learning (selective reminding test Grober and Buschke test)
Immediate cue recall (/16) 12 15 16 14
Sum of free and cued recall (/48) 21 19 20 29
Intrusions 3 12 4 6
Sum of free and cued delayed recall (/16) 3 5 8 9
Warrington’s recognition memory faces (/50) 48 NA NA NA
Executive functions
Verbal ﬂuency FAS* 9.7 (2.5) 13.3 (2.1) 10.7 (0.6) 12.7 (2.1)
Wisconsin card sorting test
Categories (/6) 6 5 6 3
Perseverative errors 1 4 3 8
Neuropsychiatric evaluation
NPI* total score (/144) 84 72 90 140
NPI apathy item – frequency (/4) 4 2 1 3
NPI apathy item – severity (/3) 2 1 1 2
NPI apathy item – stress (/5) 3 2 0 3
Dysexecutive Questionnaire (/80) 42 27 17 35
ADCS-ADL (/100)** 62 70 76 77
Cognitive difﬁculties scale Mac Nair (/80) 43 30 31 29
*NPI, Neuropsychiatric Inventory. Higher score indicates more severe impairment; **ADCS-ADL, Alzheimer’s disease cooperative study-activities of daily living
inventory. Higher score indicates less impairment.
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The neuropsychological evaluation revealed a reduced global
cognitive capacity, impairment in episodic memory and a DS with
a reduced verbal ﬂuency and cognitive ﬂexibility associated with
impaired conceptualization (Table 1).
We then proposed to the patient an open crossover study
using donepezil to assess whether this treatment could actu-
ally modify his cognitive status. The study was approved by
the local Ethics Committee (El Salvador Hospital). An informed
consent was obtained from the patient and from his wife for
the trial.
The drug was administered daily for 6months (donepezil
5mg/daily during the ﬁrstmonth, and 10mg/daily during the next
5months). The patient was assessed at baseline before treatment
and at 3 and 6months under treatment using the same neuropsy-
chological tests. A ﬁnal evaluation was carried out 3months after
discontinuation of the drug (Table 1). The questionnaires were
applied to the patient and to his wife during the same visits.
The drug was well tolerated and no adverse event was reported
by the patient. No signiﬁcant change was detected on the perfor-
mances of the different neuropsychological tests including those
sensitive to executive dysfunction such as the Frontal Assessment
at Bedside, the FCSRT and the MWCST.
In contrast, signiﬁcant changes were detected by the patient
and his wife in the behavioral outcomes assessed by the DEX
questionnaire and by the NPI severity and stress scores. “The
DEX scores improved during the treatment relative to baseline
and worsened after donepezil discontinuation. Total DEX scores
were 42, 27, and 17 points at baseline, 3 and 6months of treat-
ment, respectively. Subsequently, symptoms were increased when
medication was discontinued (total DEX score: 35). The NPI apa-
thy scores also improved under treatment and worsened with
medication discontinuation. This was observed for apathy on both
severity and stress sub-scores (see Figure 2; Table 1).”
The patient’s wife particularly reported that under the treat-
ment, the patient was much less apathetic, was more attentive,
had more initiative, and returned to working activities (he was
employed as gained employment as an auto repair center manager
while under donepezil).
DISCUSSION
The cognitive and behavioral disturbances in the present obser-
vation have been repeatedly reported in association with thalamic
infarctions. Verbal amnesia has been particularly associated with
lesions involving the anterior nucleus and mamillo-thalamic tract
of the left thalamus, dysexecutive symptoms with thalamic lesions
involving themediodorsal nucleus and/or internalmedullary lam-
ina and apathy with lesions in the anterior thalamic nucleus
(Van der Werf et al., 2003; Carrera and Bogousslavsky, 2006).
In this open label study, donepezil seems to have some ability to
modulate persisting behavioral manifestations at the late stage of
an isolated left-sided thalamic infarction. As we expected, execu-
tive performance and neuropsychiatric symptoms were improved
during treatment.
Measurable effects were detected under the treatment period
using the DEX questionnaire and the apathy sub-scores of the
NPI while no signiﬁcant changes in the other neuropsychological
tests were detected. These effects were reversed after discontin-
uation of the cholinesterase inhibitor. These behavioral changes
were also detected in the absence of signiﬁcant modiﬁcations of
the MMSE score and of episodic memory performances in line
with the poor effects of donepezil on global cognitive or memory
performances in previous vascular dementia trials (Erkinjuntti
et al., 2004; Roman et al., 2005; Dichgans et al., 2008). In this
study, not only the NPI, that is largely used for the assessment
of behavioral alterations, but also the DEX questionnaire was
applied to assess the possible changes under donepezil. The DEX
FIGURE 2 | Dysexecutive Questionnaire Score and NPI Scores for Apathy item. Performance is improved along treatment; however it is worsened when
drug intake is discontinued.
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questionnaire provides a number of advantages over the clinical
measures of executive functions. It is not limited to the evaluation
of the cognitive aspects of theDS but it also includes the evaluation
of its emotional, motivational, and behavioral components. The
questionnaire is easy to administer and includes a self-reported as
well as an informant-reported part speciﬁcally designed to assess
the participant’s behavior in daily life. Its psychometric proper-
ties on ecological and discriminative validity have been already
documented (Wilson et al., 1998).
This single-case study is a limited, preliminary clinical experi-
ence of the use of donepezil in behavioral disturbances associated
with an isolated thalamic infarction. This case study has obvious
limitations. Some ﬂuctuations of the data obtained using ques-
tionnaires, placebo effects related to the intake of a new drug
in an isolated case or multiple biases related to the non-blinded
treatment may cause that the improvement of behavior under
treatment is only detected by chance in this observation. In con-
trast, the importance of the effect with actual consequences in
daily life, the variations of the DEX scores much larger than those
reported after its repeated administration (Shinagawa et al., 2007),
the congruence of the observed effects in the present case with
data on cholinesterase inhibitors in the literature, and its partial
reversibility support that donepezil was actually efﬁcient and may
have real effects on behavior and mainly on apathy after isolated
thalamic lesions (Erkinjuntti et al., 2004; Dichgans et al., 2008).
In conclusion, the capacity of donepezil to modulate some
behavioral consequences of subcortical lesions, particularly those
related to thalamic lesions, as suggested by this observation, needs
further research. Although little is known about cholinesterase
inhibitors in vascular dementia and being this is a single-case
study, our results encourage research in groups of patients. The
present data suggests that future studies should not only focus on
the cognitive effects of cholinesterase inhibitors but also on its
behavioral effects, especially in daily life, using new and dedicated
tools for this purpose.
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